The Rheumatology Podcast

Dr James Galloway talks to Dr Carly Janssen (University of Twente, The Netherlands) about her recent papers, the first of which suggests that anakinra is non-inferior to standard of care for acute gout flares.

Dr James Galloway talks to Dr Carly Janssen (University of Twente, The Netherlands) about her recent papers, the first of which suggests that anakinra is non-inferior to standard of care for acute gout flares.

Dr James Galloway talks to Dr Carly Janssen (University of Twente, The Netherlands) about her recent papers, the first of which suggests that anakinra is non-inferior to standard of care for acute gout flares. They also discuss the importance of using robust outcome measures in clinical trials; Dr Janssen describes the Gout Attack Intensity Score (GAIS) and her hope that this measure will be used by researchers in the future.

Dr James Galloway talks to Dr Carly Janssen (University of Twente, The Netherlands) about her recent papers, the first of which suggests that anakinra is non-inferior to standard of care for acute gout flares. They also discuss the importance of using robust outcome measures in clinical trials; Dr Janssen describes the Gout Attack Intensity Score (GAIS) and her hope that this measure will be used by researchers in the future.

Dr James Galloway interviews Prof. Kimme Hyrich (University of Manchester, UK) about her work on Rheumatology’s real-world data supplement. They define real-world data and consider the future of big data collection. They also discuss the process of putting together a supplement, as well as Prof. Hyrich’s work on the BSRBR-RA Register. The real-world data supplement will be published later this year.

Dr James Galloway interviews Prof. Kimme Hyrich (University of Manchester, UK) about her work on Rheumatology’s real-world data supplement. They define real-world data and consider the future of big data collection. They also discuss the process of putting together a supplement, as well as Prof. Hyrich’s work on the BSRBR-RA Register. The real-world data supplement will be published later this year.

Dr James Galloway interviews Prof. Kimme Hyrich (University of Manchester, UK) about her work on Rheumatology’s real-world data supplement. They define real-world data and consider the future of big data collection. They also discuss the process of putting together a supplement, as well as Prof. Hyrich’s work on the BSRBR-RA Register. The real-world data supplement will be published later this year.

Dr James Galloway talks to Dr Matthew J. Koster, Mayo Clinic, Minnesota, USA, about his paper on the diagnosis, monitoring and management of large-vessel giant cell arteritis (GCA), which was published as part of our GCA supplement in 2018.

Dr James Galloway talks to Dr Matthew J. Koster, Mayo Clinic, Minnesota, USA, about his paper on the diagnosis, monitoring and management of large-vessel giant cell arteritis (GCA), which was published as part of our GCA supplement back in February, 2018. Dr Koster talks about how he initially developed an interest in GCA, before discussing the clinical challenges and recommendations highlighted within this review.

Dr James Galloway talks to Dr Matthew J. Koster, Mayo Clinic, Minnesota, USA, about his paper on the diagnosis, monitoring and management of large-vessel giant cell arteritis (GCA), which was published as part of our GCA supplement back in February, 2018. Dr Koster talks about how he initially developed an interest in GCA, before discussing the clinical challenges and recommendations highlighted within this review.